Recently, the "Bloomberg Green ESG 50 2023 Outstanding List Release Conference & Themed Dinner", co-hosted by Bloomberg Green and Bloomberg Businessweek, was successfully held in Suzhou. Sino Biopharm stood out from hundreds of participating companies for its outstanding performance in ESG governance in recent years, winning the "The 2023 Bloomberg Green ESG 50 Companies: Governance".

As investors, enterprises, and professional institutions continue to deepen their focus on ESG, Bloomberg Green launched the "Bloomberg Green ESG 50 2023" selection event in 2023. It aims to recognize enterprises that made outstanding contributions in the ESG field in 2023, promote in-depth communication and sharing among enterprises on ESG construction, and build a green economic system. This selection was conducted in cooperation with the globally renowned accounting firm Deloitte, and an expert judging panel composed of authoritative domestic and international experts with prestige and expertise in the ESG field was invited. After nearly half a year, the "Bloomberg Green ESG 50 2023 List" was released.

As a leading innovation and R&D-driven pharmaceutical group, Sino Biopharm is committed to achieving outstanding corporate governance performance. It continuously enhances the professionalism, independence, and diversity of its Board of Directors, aiming to consistently improve the decision-making capabilities of the governance level and provide strong support for the Group's "innovation + internationalization" strategic development.

In terms of ESG governance, the Group upholds the corporate mission of "improving the quality and protecting the dignity of human life". It has formulated the "CARE" ESG governance strategy centered on "Cure, Accessible, Relationship, and Environmental". It has established and implemented a "three-tier ESG management system" from the "Board of Directors decision-making level" to the "Group senior management level" and the "enterprise executive level". This effectively ensures the comprehensive implementation of the ESG governance strategy, continuously promotes the organic integration of ESG management with the Group's overall development strategy, and provides a guarantee for the harmonious and sustainable development of the company, employees, society, and the environment.

This selection represents the recognition of Sino Biopharm's excellent practical performance in the field of ESG governance by professional ESG institutions, and also reflects the significant progress Sino Biopharm has made through its continuous deep efforts in the ESG field. In the future, Sino Biopharm will continue to practice the ESG concept and enhance its ESG governance level. With good corporate governance as the cornerstone, it will create long-term value for itself and partners from all sectors.